Welcome Guest! To enable all features please  Log In or Register

ALS Resources


Favorites

Log In or Register to see a list of your favorite topics.
Wild-type bone marrow stem cell for ALS
Bernard
Posted: Tuesday, September 26, 2006 9:21:21 PM
Rank: Newbie

Groups: Member

Joined: 11/8/2005
Posts: 201
Location: USA
][Article in Chinese]
Huang H, Zhang C, Zhao CP, Yao XL, Xi J.
Department of Neurology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China.

OBJECTIVE: To determine the effects of wild-type mouse bone marrow stem cells transplants on survival time and motor functions in the human mutant SOD1-G93A mouse model of familial amyotrophic lateral sclerosis (ALS). METHODS: Bone marrow stem cells derived from the wild-type male mice were delivered intravenously into 25 ALS transgenic female mice (carrying the human SOD1 gene with Gly 93 Ala mutation) that had been pretreated with 5.5-6.5 Gy gamma-ray 5-7 days before. The onset time of limbs paralysis, lifespan and the graft versus host disease (GVHD) symptoms were observed in the treated group and statistically compared with control group of 15 media-injected ALS transgenic mice. The Sry gene (sex determine region on the Y chromosome) were detected by polymerase chain reaction technique in the blood sample of treated female ALS mice after 8 weeks of transplantation. A series of animal motor tests including rotating rods, rotated wheel and extension reflex were performed in both two groups at the same age of 16-17 weeks to assess the mice survival motor functions. Results A few treated mice (7/25) had different clinical presentations of GVHD. The semi-quantity evaluation score of average GVHD among the treated ALS mice was not over 1-2. The detection of Sry gene on these treated female ALS group was positive. The average onsets of limb paralysis and survival time were prolonged for about 5 weeks. At the age of 16-17 weeks, the motor function in the treated group was significantly better than in the ALS control group (P < 0.01). CONCLUSIONS: Transplantation of wild-type mice bone marrow stem cells can prolong survival in the recipient mice and ameliorate motor dysfunction. Intravenous administration of normal bone marrow stem cells may have therapeutic values for ALS.

PMID: 16995314 [PubMed - in process]
jmccarty
Posted: Wednesday, September 27, 2006 4:12:58 PM

Rank: Advanced Member

Groups: Administration , Member

Joined: 1/15/2009
Posts: 2,276
Location: Cambridge , MA
Thanks Dan for posting: I can’t be sure as it’s difficult for me to trace down but I would suspect that the H. Huang here is the same person doing the ‘stem cell’ transplants in exchange for a large fee with SCI and ALS patients. That contingency alone, if verified, would be sufficient to place large doubts on the validity of the conclusions. Furthermore, if so, the motivations of the publication could be called into question.

Other than that, there are a fair number of researchers looking into different variations on stem cells (of which marrow cells could be considered a type of) in treating ALS. The mode of action in the paper above (I’m assuming) could be along the lines that immune cells, expressing SOD1 and thus in some way toxic, are making their way to the spine and potentiating progression. Inflammation has a role in ALS that still remains to be understood but the reliance on the immune cells (outside the resident glial cells) expressing SOD1 as part of the scenario seems at this point more complicated than necessary. Nature is nothing but capricious; however, putting higher confidence in this result would require more research and independent repetition (and an even further repetition if the identity is as discussed in the above paragraph). The first link below provides potentially a separate report but the details are difficult to extract from the abstract.


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15469951&query_hl=18&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16808883&query_hl=18&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16518833&query_hl=18&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16242126&query_hl=18&itool=pubmed_docsum


John McCarty, PhD
Treatment Investigator,
ALS Therapy Development Foundation

John McCarty, PhD
Director of Therapeutic Investigation
ALS Therapy Development Institute
Users browsing this topic Guest

Forum Jump
You cannot post new topics in this forum.
You cannot reply to topics in this forum.
You cannot delete your posts in this forum.
You cannot edit your posts in this forum.
You cannot create polls in this forum.
You cannot vote in polls in this forum.


Powered By Yet Another Forum
This page was generated in 0.242 seconds.